Legal Representation
Attorney
Andrea L Calvaruso
USPTO Deadlines
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 16, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 16, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 16, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 16, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 16, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 14, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 9, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 9, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 3, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Sep 17, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Sep 16, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Aug 7, 2025 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Aug 6, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 5, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 28, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 28, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 24, 2025 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and biological preparations for the treatment of cancer and non-cancer fibrotic and inflammatory diseases for medical purposes; monoclonal antibodies for medical use; pharmaceutical preparations for the prevention, diagnosis and treatment of cancer and immune-mediated inflammatory and autoimmune diseases, namely tenosynovial giant cell tumor (TGCT), graft-versus-host disease, acute myeloid leukemia, chronic myelomonocytic leukemia, soft-tissue sarcoma, ovarian cancer, triple-negative breast cancer, head and neck cancer, malignant meningioma, T-cell lymphoma, osteosarcoma, glioblastoma, follicular lymphoma and malignant pleural mesothelioma; diagnostic reagents for medical purposes for use in connection with tenosynovial giant cell tumor (TGCT), graft-versus-host disease, acute myeloid leukemia, chronic myelomonocytic leukemia, soft tissue sarcoma, ovarian cancer, triple-negative breast cancer, head and neck cancer, malignant meningioma, T-cell lymphoma, osteosarcoma, glioblastoma, follicular lymphoma and malignant pleural mesothelioma
Class 042
Scientific and medical research; pharmaceutical research and development; drug discovery services; pharmaceutical product development; testing of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; clinical scientific research in the fields of oncology and immunology; providing medical and scientific research information in the fields of oncology and immunology; design and development of pharmaceutical preparations and medicines
Additional Information
Translation
The wording YUQENA has no meaning in a foreign language.
Classification
International Classes
005
042